SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094084
Filing Date
2024-08-08
Accepted
2024-08-08 16:30:33
Documents
89
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sabs-20240630.htm   iXBRL 10-Q 2293590
2 EX-10.2 2021 OMNIBUS EQUITY INCENTIVE PLAN, AS AMENDED sabs-ex10_2.htm EX-10.2 232595
3 EX-31.1 sabs-ex31_1.htm EX-31.1 22275
4 EX-31.2 sabs-ex31_2.htm EX-31.2 22367
5 EX-32.1 sabs-ex32_1.htm EX-32.1 9659
6 EX-32.2 sabs-ex32_2.htm EX-32.2 9991
7 GRAPHIC img153677521_0.jpg GRAPHIC 32063
  Complete submission text file 0000950170-24-094084.txt   10952465

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20240630.xsd EX-101.SCH 1751546
92 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20240630_htm.xml XML 1824715
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

IRS No.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39871 | Film No.: 241188955
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)